# Trevi Therapeutics, Inc. (TRVI)

> Source: Nexqual · https://nexqual.com/TRVI · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Trevi Therapeutics, Inc. (TRVI), nexqual.com/TRVI" · informational, not investment advice.

**Price:** USD 12.94 (+1.33% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 12.77 · day 12.53–13.22 · 52w 9.82–20.22 · market cap $1.84B · NGM

## Key facts
- 1 of 80 tracked superinvestors hold TRVI (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Total return with dividends: 1Y +21.5% vs S&P 500 +14.9%; 5Y +960.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD -0.13, revenue estimate $0K.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold TRVI. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.08% | $28.8M | Reduced -51.7% |

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Jones Trading | Target raised | Buy | $24 → $28 |
| 2026-08-07 | Oppenheimer | Target raised | Outperform | $24 → $25 |
| 2026-08-07 | Cantor Fitzgerald | Target raised | Overweight | $25 → $30 |
| 2026-07-21 | BMO Capital | Initiated | Outperform | $36 |
| 2026-07-20 | B. Riley Securities | Target raised | Buy | $21 → $31 |
| 2026-07-20 | HC Wainwright & Co. | Target raised | Buy | $21 → $24 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +21.5% | +960.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +21.6% | +60.2% |
| Volatility (annualized) | 57.5% | 93.2% |
| Max drawdown | -39.1% (Jul 2026→Oct 2026) | -73.0% (Aug 2022→Nov 2023) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/TRVI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.13 | $-0.13 | +3.1% | $0 | 10 |
| Next quarter (ends 2026-12-31) | $-0.14 | $-0.14 | +3.6% | $0 | 10 |
| Current fiscal year (ends 2026-12-31) | $-0.48 | $-0.46 | +3.2% | $0 | 10 |
| Next fiscal year (ends 2027-12-31) | $-0.58 | $-0.56 | +3.4% | $0 | 10 |